Qbic et al. invest €2m in Biogazelle

Qbic invested in the company via its Arkiv Fund, a joint venture capital vehicle with Arkimedes Fund II, a €100m Flemish fund-of-funds initiative that provides capital to match the amount already raised by a venture capital fund.

PMV invested from the €20m Spin-off Financing Instrument (Sofi) fund, a Flemish government-established fund that the state-backed firm manages.

In July this year, the two firms – via the same funds – jointly invested €500,000 in Pharmafluidics, a Belgian developer of micro-fabrication engineering technology.

Fournier-Majoie is a Belgian non-profit organisation that supports entrepreneurs who are developing products that would benefit cancer patients. As of March this year, the foundation had invested €3.5m in projects and allocated a total of €4.8m.

Company
Founded in 2007 as a Ghent University spinout, Biogazelle has developed qbase+, a real-time polymerase chain reaction data analysis software.

The company also provides laboratory services such as ribonucleic acid extraction and sequencing. It claims to have achieved an annual growth rate of 70%.

People
CEO Jan Hellemans and CSO Jo Vandesompele founded Biogazelle.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Expansion
• Technology
• Belgium